Background: Viral infections are imported by travelers and immigrants from tropical or subtropical regions. The primary care physician should be able to include these diseases in the differential diagnosis of various clinical conditions.
Methods: This review is based on pertinent articles retrieved by a selective search of the literature, including guidelines from Germany and abroad.
Results: The available data on imported viral infections in Germany constitute low-level evidence, because most such infections are not reportable in this country. Useful data have, however, been collected by international surveillance networks. Imported viral infections usually present with fever, often also with a rash and elevated transaminases. An average of 230 cases occur in Germany each year; the most common diagnosis among them is dengue fever. An imported viral infection should also be included in the differential diagnosis of fever with arthralgia, as chikungunya virus causes an average of 38 such cases per year. On the other hand, in the past two years, there have been only five cases of imported viral infections causing encephalitis (West Nile virus and Japanese encephalitis virus).
Conclusion: The primary care physician should take a thorough history so that specifically targeted laboratory tests can be ordered as soon as possible. If the suspicion of an imported viral infection is confirmed, the patient should be transferred to a specialized treatment center.
Data on the epidemiology of diseases imported by travelers and immigrants are available from worldwide surveillance networks. The most important one is the GeoSentinel network, sponsored by the International Association of Travel Medicine and the Centers for Disease Control and Prevention (CDC), Atlanta, USA (1), which has collected data on more than 180 000 travelers as of September 2012. Imported infections usually present with fever, diarrhea, or a rash; other symptoms, such as arthralgia, are rarer. Studies of imported viral diseases have shown that dengue fever is becoming more common in Germany (2–4).
This article will help readers to
Viruses: general characteristics
Viruses are obligate intracellular parasites that need a host cell to reproduce themselves (replicate). They have no metabolic apparatus of their own and contain only one kind of nucleic acid, either DNA or RNA.
In tropical regions, many viruses are transmitted to man by arthropods (mosquitoes in particular) and are thus called arthropod-borne viruses, or arboviruses for short (2). The arboviruses and mosquito vectors that were once found only in the tropics are now increasingly seen in Europe (including Germany) as a result of international passenger travel and trade. They can now cause local outbreaks of disease here as well (4).
The primary care physician should know that arboviral disease is usually diagnosed by the indirect demonstration of the pathogen. An infection can be proved beyond any doubt by the detection of virus-specific IgG and IgM antibodies in the patient’s serum (Table). The nucleic acids of most arboviruses can only be directly detected in the serum in the first week of the illness (Table).
The differential diagnosis of fever
Fever after travel in tropical regions
Fever must be evaluated immediately, as it may be a sign of an acutely life-threatening illness (Box 1). Heading the differential diagnosis is malaria, the most common imported illness, with an average of 638 cases in Germany per year. Further diagnoses that should always be considered in cases of monosymptomatic fever are typhus, paratyphus, and amoebic liver abscess (Box 1) (2). The most common imported viral disease is dengue fever, with an average of 230 cases in Germany per year. Dengue virus infection is the leading cause of fever in persons returning from Southeast Asia (3).
Dengue fever (DF) is caused by dengue viruses (DENV), of which there are four serotypes. It is endemic in tropical and subtropical regions around the world. In 2010, the first indigenous cases of dengue fever were diagnosed in the south of France and in Croatia (4). DENV is mainly transmitted by the yellow fever mosquito (Aedes aegypti), but an increasing number of cases are now being transmitted by the Asian tiger mosquito (Aedes albopictus).
DF is among the illnesses that are often imported from tropical and subtropical regions (5, 6). Typical source countries are Thailand, India, Brazil, and the Caribbean islands. Recent years have seen a rising number of cases imported to Germany and reported to the Robert Koch Institute (RKI), the German analogue of the CDC (Figure 1).
After an incubation period of 4 to 7 days (maximum, 14 days), the disease usually begins abruptly with fever up to 40°C (Table). Often, shaking chills, severe retro-orbital headache, and conjunctivitis follow, and the fever persists for 48 to 96 hours (2). Skin erythema is common, mainly on the face and chest, often with white dermatographism (Figure 2). The fever is often, but not always, biphasic: after transient defervescence, the temperature rises again. At this time, about half of all patients develop a maculopapular rash (2). There is usually a mild elevation of transaminases, along with thrombocytopenia and lymphopenia. The characteristic triad consists of fever, rash, and pain in the head, muscles, and joints. Once the acute disease has subsided, there is long-lasting serotype-specific immunity, but only a brief period of cross-immunity. Thus, after a short time, the patient is no longer protected against infection with other DENV serotypes (2). In severe cases, DF can cause hemorrhage; such cases, known as dengue hemorrhagic fever (DHF), are mainly seen among children in hyperendemic areas (2). DHF can also present as dengue shock syndrome (DSS), which is characterized by fewer hemorrhages, but also by a massive shifting of fluid from the intravascular compartment into the tissues. DENV secondary infections seem to be of the DHF type more commonly than primary infections are, owing to an intensification of infection by antibodies. Persons returning from endemic areas with DENV infections usually have an illness of the DF type (6); fewer than 1% have DHF. There has been only one death from DHF in Germany to date (7).
A newly arisen DENV infection can be diagnosed by the demonstration of DENV-RNA, DENV-NS-1 antigen, or DENV-specific IgG and IgM antibodies (Table and Figure 3). Serologic testing in the first three weeks after disease onset should always include simultaneous testing for NS-1, IgM and IgG, for maximal clinical sensitivity and specificity (7).
Patients with dengue fever should be observed until their laboratory values have renormalized. They may need to be hospitalized in case of severe thrombocytopenia, petechiae or other signs of hemorrhage, or elevated transaminases (8). There is no available treatment directed at the cause of the disease. Drugs with anticoagulant effects (e.g., acetylsalicylic acid) are contraindicated. If the hematocrit rises by more than 20%, intravenous fluids should be given early to prevent DSS. Vaccines agains DENV infections are now being developed (phase 3), but the initial findings on their putative effectiveness are not promising (9) and no vaccine is expected to be approved in the next few years. Persons traveling to Southeast Asia or South America should observe 24-hour precautions against mosquito exposure.
Sandfly fever is transmitted by Sandfly fever Naples virus and Sandfly fever Sicilian virus (SFNV, SFSV) and the Toscana virus (TOSV) (2). These viruses usually cause fever without any other accompanying symptoms; they are found throughout the Mediterranean region, all the way to Asia Minor, corresponding to the geographical distribution of their vector, the sandfly Phlebotomus spp. (2). TOSV, however, can also cause aseptic meningitis. TOSV infections have been observed in Europe in recent years in Italy, Spain, Portugal, France, and Cyprus; they usually arise in summer and are one of the most common causes of aseptic meningitis in Italy (2). Returning travelers are often among the affected persons (10). From the first week of infection onward, the diagnosis can be made serologically by the demonstration of anti-SFNV, -SFSV, or -TOSV antibodies (IgG and IgM) in the patient’s serum (Table). There is no specific, causally directed treatment for sandfly fever. Antipyretic and analgesic drugs can be given symptomatically (2).
The differential diagnosis of viral hemorrhagic fever (VHF)
Viral hemorrhagic fever in general
Viral hemorrhagic fever (VHF) should be included in the differential diagnosis when a patient presents in a severely ill state with marked elevation of serum transaminases and signs of renal involvement or a hemorrhagic diathesis (Box 1). These diseases are very rarely imported (2), but they are life-threatening (11). Lassa virus infections have only been imported to Germany twice to date, and Ebola virus infections not at all (2). Some VHF viruses can be transmitted directly from person to person, possibly in respiratory droplets (Lassa, Ebola, Marburg, and Crimean-Congo hemorrhagic fever virus); this fact has major implications for clinical management because of the risk of nosocomial transmission (11). In contrast, imported yellow-fever–virus infections and dengue-virus infections are not contagious, so these patients do not need to be isolated. In suspected cases of VHF, the patient should be isolated at the site of diagnosis if possible, and the responsible public-health authorities should be informed so that they can arrange transport of the patient, under strict isolation precautions, to a competence center for the appropriate treatment. The goal is to provide optimal medical treatment for the patient while minimizing the risk of spread to other persons, including the treating team (12). There are a number of high-security isolation wards of this type in Germany (Box 2).
The primary care physician should think of VHF when the patient has a fever above 38.5°C, has been in sub-Saharan Africa in the past three weeks, and may have had contact there with persons suffering from VHF, or is already suffering from a hemorrhagic diathesis or unexplained shock. Important elements of the differential diagnosis are malaria, fulminant viral hepatitis, leptospirosis, meningococcal sepsis, and intoxications of various kinds (13).
The diagnostic assessment, which must be carried out in a high-security laboratory (see eBox), relies mainly on the demonstration of the RNA of the viral pathogen using reverse transcriptase polymerase chain reaction (RT-PCR) in the first week of the illness (Table). Virus-specific IgG and IgM antibodies can be detected in the serum from the second to fourth week of disease onward (Table), but this test is often still negative (2).
Lassa fever is named after the town in northeastern Nigeria where, in 1969, the disease was first described and the Lassa virus (LASV) was first isolated. It is endemic to Sierra Leone, Guinea and Liberia in the west and Nigeria in the east, and in a number of other West African countries. The virus’s natural host is the African rodent Mastomys natalensis. Most LASV infections are mild or asymptomatic. An estimated 100 000 to 300 000 persons become infected with LASV each year, of whom 1% to 2% die (2). Only two cases are known to have been imported to Germany in recent years (2). The overt illness usually presents nonspecfically with fever, headache, sore throat, coughing, and gastrointestinal symptoms. Typically, there is progressively severe edema of the eyelids and face, along with conjunctivitis, severe myalgia, proteinuria, hypotension, ulcerating pharyngitis (sometimes with laryngeal edema), coughing, nausea, and vomiting. Thereafter, pneumonia, hepatitis, encephalitis, and hemorrhagic fever can develop, the latter potentially leading to multi-organ failure. High GOT values and marked viremia are unfavorable prognostic signs. The patients often do not appear seriously ill until shortly before they develop multi-organ failure. The disease is particularly serious in pregnant women. Post-exposure prophylaxis with ribavirin is recommended for persons who have had unprotected, direct contact with the blood or bodily fluids of patients with Lassa fever (14).
Ebola and Marburg hemorrhagic fever
The Ebola and Marburg viruses are among the more dangerous pathogens known to medical science. Types that can infect human beings are found only in sub-Saharan Africa (15). Marburg virus was discovered in Marburg, Germany, in 1967, when a number of laboratory workers there, and in what was then Yugoslavia, became acutely ill with a fever of unknown origin. This first epidemic of Marburg fever was caused by the transport of infected primates from Uganda to Europe for research purposes (2). Two further, highly lethal ones occurred, in 1998–2000 in the northern region of the Democratic Republic of the Congo (DRC) and in 2004–2005 in Angola (2). Ebola virus was first described in 1976, when it caused large epidemics in Zaire (now the Democratic Republic of the Congo) and in the Sudan (15). Further epidemics have occurred in Central Africa in recent years. 2300 cases of Ebola fever and 450 of Marburg fever have been registered to date (2).
Travelers very rarely import these viruses into non-endemic regions. Two imported filovirus infections were treated in South Africa (15). In 2008, a woman imported a case of Marburg fever from Uganda to the Netherlands (16). The natural reservoir of this virus is in fruit bats; there have been a few cases of travelers who were infected on visits to fruit-bat caves, by direct contact with the animals or their infectious excreta (15). Contact with infected primates can also lead to infection (15).
The incubation time of Ebola virus is generally 2–25 days, while that of Marbug virus is generally 5–7 days, rarely as long as 10 days (Table). The affected patients suddenly develop fever, severe headache, arthralgia, myalgia, chest pain, abdominal pain, and loss of appetite. Fairly typical findings include pharyngitis, conjunctival infection, and a morbilliform, non-pruritic, non-hemorrhagic rash that is readily visible, particularly on white skin (15). Gastrointestinal symptoms are common, including bloody diarrhea in fatal cases. There is a generalized bleeding tendency, with epistaxis, hematuria, hemoptysis, hematemesis, metrorrhagia, and spontaneous abortion (days 5–7 of illness). Neurological and psychiatric manifestations (hemiparesis, psychosis) are also common, and anuria may develop. In fatal cases, death usually occurs from day 6 to day 16 of the illness. Survivors may suffer from myelitis, hepatitis, psychosis, or uveitis (15).
Crimean-Congo hemorrhagic fever
Crimean-Congo hemorrhagic fever (CCHF) is caused by the virus of the same name (CCHFV), which was first isolated and characterized in the Belgian Congo (now the DRC) and originally known as Congo virus (2). In the 1970’s, this virus was shown to be identical to the pathogen causing hemorrhagic Crimean fever, a disease that had been known since 1944 (2). CCHFV is the most geographically widespread tick-borne virus. It is usually transmitted by ticks of the genus Hyalomma and is endemic to many countries of Africa, Asia, Southeastern Europe, and the Middle East. It can infect many different vertebrates (both wild and domestic), but animals, unlike humans, do not become ill when infected. Transmission to man is either through a tick bite or by contact with infected animals. The risk of transmission from a hospitalized patient with CCHF to other persons is high: A number of highly lethal nosocomial outbreaks have been documented, most recently in Turkey and Kazakhstan. Only two imported cases have been registered in Germany in the last five years (17).
In man, cases of CCHF infection can range in severity all the way from an asymptomatic state, to a flu-like course, to a highly lethal hemorrhagic fever. Fever arises suddenly after a 2–13 day incubation period (Table). Further manifestations include malaise, weakness, irritability, headache, pain in the limbs, loss of appetite, and sometimes vomiting, diarrhea, and epigastric pain. Hemorrhage may occur after only a few days of illness and may be massive, with cutaneous hemorrhage, gastrointestinal bleeding, or hematemesis, often combined with liver dysfunction (2). 10% to 50% of the affected patients die, usually 5 to 14 days after the onset of the disease (2).
Viral infections characterized by persistent arthralgia
The causes of arthralgia after travel to tropical regions
Returning travelers often complain of arthralgia (18). The possible causes include post-infectious arthritis and viral illness. In the tropics, certain arboviruses are particularly strongly associated with arthritis (Table).
This disease is mainly found in eastern and southern Africa, on the Indian subcontinent, in Southeast Asia, and (in recent years) on islands in the Indian Ocean (2). Seasonal outbreaks are now occurring in southern Europe as well, e.g., in Italy in 2007 (19). The main explanation for the latter is the increase in international travel and trade, but the wide distribution of competent mosquito vectors in Southern Europe also increases the danger of indigenous infection. Chikungunya virus (CHIKV) is transmitted by various mosquito species (especially Aedes albopictus) from a reservoir of various warm-blooded animals (rodents, non-human primates, and others) to other warm-blooded animals.
After a 2- to 12-day incubation period, patients develop sudden, rapidly rising fever, headache, conjunctivits, myalgia, and arthralgia. Arthralgia is a prominent symptom, usually bilateral and mainly affecting the limbs (2). The joints are swollen and tender. There may be a maculopapular rash or generalized redness of the skin. The fever may take a biphasic course. A small percentage of patients (5–10%) have arthralgia that persists for months or, rarely, years (2). CHIKV infection can be diagnosed in the first few days of the illness by the detection of viral RNA in the patient’s serum with RT-PCR (Table) (2). IgM and IgG antibodies can only be detected from the second week of illness onward (Table).
There is no specific treatment for chikungunya fever. It is treated symptomatically with nonsteroidal anti-inflammatory agents and other drugs (2). The only means of prevention is round-the-clock protection against mosquitoes.
Ross River fever or epidemic polyarthritis
Ross River fever is the most common mosquito-borne viral infection in Australia (23). It is characterized by persistent arthralgia and thus causes considerable morbidity, with corresponding economic effects. There are an average of 4,800 cases in Australia each year (23). The disease is also endemic to Papua New Guinea, and there have been major outbreaks in Fiji, Samoa, the Cook Islands, and New Caledonia (23). Ross River fever should be included in the differential diagnosis of arthralgia in returning travelers with a suggestive history (23, 24).
The incubation period is usually 3–14 days, but can rarely be as long as 21 days (Table). Asymptomatic infection is apparently common. Further typical clinical features include fever, a maculopapular rash, and persistent arthragia (epidemic polyarthritis). Fever and rash arise in 50% of patients (2). The rash usually lasts 5 to 10 days and is mainly on the limbs and trunk. Most patients acutely develop symmetrical arthritis, mainly in the peripheral joints (2). In about half of all patients, arthritis lasts more than a year.
From the second week of illness onward, Ross-River-virus-specific IgG and IgM antibodies can be detected in the patient’s serum (Table). The treatment is symptomatic, with non-steroidal anti-inflammatory drugs (2).
Meningoencephalitis acquired in tropical regions
Meningoencephalitis acquired in tropical regions has an extensive differential diagnosis. Cerebral malaria is always a possibility after a trip to sub-Saharan Africa (2). The meningoencephalitic stage of sleeping sickness, though rare, should also be considered. Viral illnesses are listed in the Table according to the geographical regions where they can be acquired.
West Nile fever
West Nile Virus (WNV) is a mosquito-borne virus that was first isolated from the blood of a Ugandan woman in 1937. The first documented epidemic occurred in Israel in 1950. WNV is a classic example of an “emerging virus”: It appeared in North America in 1999, then spread to cause 1.8 million infections in North America by 2010, with at least 1308 fatalities (25). Clearly, even well-developed countries are not spared the danger of epidemic disease from imported, mosquitoes-borne viruses. WNV is now widespread on all five inhabited continents; there were major outbreaks in Europe in 2010 and 2011 (26). The last major outbreak was in Greece in 2010, with 197 cases, 33 of them fatal (26). A number of avian species serve as a reservoir for the virus by being a source of infection for blood-sucking mosquitoes. Aside from human beings, horses can also become ill with West Nile fever.
The importation of WNV to Germany is only to be expected, because the mosquito vector (the common house mosquito) is found throughout Germany and WNV is already circulating in neighboring countries (France, Austria, and the Czech Republic). In 2011, we documented the first imported WNV infection in Germany (from Canada) (27). In 2012, there were two further cases of imported WNV infection, this time from within Europe (Montenegro and Greece). The incubation time in man is 2 to 15 days (Table). Most infections are subclinical (80%) or have nonspecific symptoms (26). The fever curve may be biphasic. Half of all patients have a maculopapular rash (2). The disease can be complicated by inflammation of the central nervous system—meningitis, encephalitis, encephalomyelitis, or polyradiculitis. The risk of neurological complications is higher in the elderly and in persons with pre-existing cardiovascular disease (26). Among elderly patients, WNV meningoencephalitis carries a mortality of 5–10%.
WNV infection can be diagnosed in its early stages by the detection of viral RNA in the patient’s serum or cerebrospinal fluid with RT-PCR (Table). WNV-specific IgM and IgG antibodies are detectable only from the second week of illness onward (Table). In serological diagnosis, it must be borne in mind that cross-reactions with other flaviviruses can occur. There is no specific treatment for WNV infection (2).
Japanese encephalitis, caused by a virus of the same name (abbrevated JE virus), is the most common type of viral encephalitis in Asia, with 30 000 to 50 000 cases reported per year (2). Its area of distribution ranges from the west Pacific islands to the eastern border of Pakistan, and from Korea to northern Australia (Figure 4). Several species of water fowl and pigs that are kept in human habitations serve as viral reservoirs and amplifying hosts. The virus is transmitted by nocturnally active mosquitoes of the genus Culex, most frequently by the rice-paddy mosquito, C. tritaeniorhynchus. The disease is found mainly in rural areas with rice paddies and in areas abundant in water and swampland. Recently, cases have also been seen in cities in the endemic areas (2).
JE virus infection was hardly a concern for travelers from Germany until quite recently. In the last few years, however, two German vacationers have developed the illness (28). A vaccine is available for travelers at risk (29). JE virus infection usually manifests itself as a mild, flu-like febrile illness. In about one in 250 cases, however, acute meningoencephalitis develops: Fever, headache, and vomiting are followed by impairment of consciousness, abnormal reflexes, confusion, altered behavior, tremor, or paresis (2). Neuro-imaging may reveal hemorrhagic lesions in the thalamus (30). Defervescence usually begins after the tenth day of illness. CNS involvement carries a 30% mortality, and permanent neurological and neuropsychological damage is common among survivors. Survivors have lifelong immunity. Dengue fever, another potential cause of encephalitis, should be considered in the differential diagnosis.
JE virus infection can be diagnosed in the first few days of illness by the detection of viral RNA in the patient’s serum or CSF with RT-PCR (Table). JE-virus-specific IgM and IgG antibodies can be detected from the second week of illness onward (Table). In serological diagnosis, it must be borne in mind that cross-reactions with other flaviviruses can occur. There is no specific treatment for JE virus infection (2).
Conflict of interest statement
The authors declare that no conflict of interest exists.
Manuscript submitted on 8 May 2012, revised version accepted on 25 September 2012.
Translated from the original German by Ethan Taub, M.D.
Dr. med. Jonas Schmidt-Chanasit
Bernhard-Nocht-Institut für Tropenmedizin
20359 Hamburg, Germany
@eBox availble at:
|1.||Cramer J, Burchard GD, von Sonnenburg F: Sentinel-Surveillance-Netzwerke: Reiseassoziierte Erkrankungen frühzeitig erkennen Dtsch Arztebl 2011; 108(48): A 2594–7. VOLLTEXT|
|2.||Löscher T, Burchard GD: Tropenmedizin in Klinik und Praxis, |
4. Auflage. Stuttgart: Georg Thieme Verlag 2010.
|3.||Wilson ME, Weld LH, Boggild A, et al.: Fever in returned travelers: Results from the GeoSentinel Surveillance Network. Clin Infect Dis 2007; 44: 1560–8. CrossRef MEDLINE|
|4.||Schmidt-Chanasit J, Haditsch M, Schöneberg I, Günther S, Stark K, Frank C: Dengue virus infection in a traveller returning from Croatia to Germany. Euro Surveill 2010; 15: 19677. MEDLINE|
|5.||Chen LH, Wilson ME: Dengue and chikungunya infections in travelers. Curr Opin Infect Dis 2010; 23: 438–44. CrossRef MEDLINE|
|6.||Wichmann O, Gascon J, Schunk M, et al.: Severe dengue virus infection in travelers: risk factors and laboratory indicators. |
J Infect Dis 2007; 195: 1089–96. CrossRef MEDLINE
|7.||Schmidt-Chanasit J, Tenner-Racz K, Poppert D, et al.: Fatal dengue hemorrhagic fever imported into Germany. Infection 2012; 40: 441–3. CrossRef MEDLINE|
|8.||Hochedez P, Canestri A, Guihot A, et al.: Management of travelers with fever and exanthema, notably dengue and chikungunya infections. Am J Trop Med Hyg 2008, 78: 710–13. MEDLINE|
|9.||Sabchareon A, Wallace D, Sirivichayakul C, et al.: Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet. 2012 Sep 10. pii: S0140–6736(12)61428–7. CrossRef MEDLINE|
|10.||Gabriel M, Resch C, Günther S, Schmidt-Chanasit J: Toscana virus infection imported from Elba into Switzerland. Emerg Infect Dis 2010; 16: 1034–6. CrossRef MEDLINE|
|11.||Beeching NJ, Fletcher TE, Hill DR, Thomson GL: Travellers and viral haemorrhagic fevers: what are the risks? Int J Antimicrob Agents 2010; 36(Suppl 1): S26–35. CrossRef MEDLINE|
|12.||Fusco FM, Schilling S, De Iaco G, et al.: EuroNHID Working Group. Infection control management of patients with suspected highly infectious diseases in emergency departments: data from a survey in 41 facilities in 14 European countries. BMC Infect Dis 2012; 12: 27. CrossRef MEDLINE|
|13.||Woodrow CJ, Eziefula AC, Agranoff D, et al.: Early risk assessment for viral haemorrhagic fever: experience at the Hospital for Tropical Diseases, London, UK. J Infect 2007, 54: 6–11. CrossRef MEDLINE|
|14.||Bausch DG, Hadi CM, Khan SH, Lertora JJ: Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever. Clin Infect Dis 2010; 51: 1435–41. CrossRef MEDLINE|
|15.||Feldmann H, Geisbert TW: Ebola haemorrhagic fever. Lancet 2011; 377: 849–62. CrossRef MEDLINE|
|16.||Van Paassen J, Bauer MP, Arbous MS, et al.: Acute liver failure followed by multi-organ failure and cerebral edema associated with activation of pro- and anti-angiogenic factors in a case of Marburg hemorrhagic fever. Lancet Infect Dis 2012; 12: 635–42. CrossRef MEDLINE|
|17.||Ölschläger S, Gabriel M, Schmidt-Chanasit J, et al.: Complete sequence and phylogenetic characterisation of Crimean-Congo hemorrhagic fever virus from Afghanistan. J Clin Virol 2011; 50: 90–2. CrossRef MEDLINE|
|18.||Kivity S, Meltzer E, Bin H, Schwartz E: Protracted rheumatic manifestations in travelers. J Clin Rheumatol 2011; 17: 55–8. MEDLINE|
|19.||Angelini R, Finarelli AC, Angelini P, et al.: An outbreak of chikungunya fever in the province of Ravenna, Italy. Euro Surveill 2007; 12: E070906.1. MEDLINE|
|20.||Frank C, Schöneberg I, Stark K: Trends in imported chikungunya virus infections in Germany, 2006–2009. Vector Borne Zoonotic Dis 2011; 11: 631–6. CrossRef MEDLINE|
|21.||Odolini S, Parola P, Gkrania-Klotsas E, et al.: Travel-related imported infections in Europe, EuroTravNet 2009. Clin Microbiol Infect 2012; 18: 468–74. CrossRef MEDLINE|
|22.||Taubitz W, Cramer JP, Kapaun A, et al.: Chikungunya fever in travelers: clinical presentation and course. Clin Infect Dis 2007; 45: e1–4. CrossRef MEDLINE|
|23.||Tappe D, Schmidt-Chanasit J, Ries A, et al.: Ross River virus infection in a traveller returning from Northern Australia. |
Med Microbiol Immunol 2009; 198: 271–3. CrossRef MEDLINE
|24.||Cramer JP, Kastenbauer U, Löscher T, et al.: Polyarthritis in two travellers returning from Australia. J Clin Virol 2011; 52: 1–3. CrossRef MEDLINE|
|25.||Kilpatrick AM: Globalization, land use, and the invasion of West Nile virus. Science 2011; 334: 323–7. CrossRef MEDLINE|
|26.||Danis K, Papa A, Theocharopoulos G, et al.: Outbreak of West Nile virus infection in Greece, 2010. Emerg Infect Dis 2011; 17: 1868–72. CrossRef MEDLINE PubMed Central|
|27.||Schultze-Amberger J, Emmerich P, Guenther S, et al.: West Nile virus meningoencephalitis imported into Germany. Emerg Infect Dis 2012; 18:1698–700. CrossRef MEDLINE|
|28.||Tappe D, Nemecek A, Zipp F, et al.: Two laboratory-confirmed cases of Japanese encephalitis imported to Germany by travelers returning from Southeast Asia. J Clin Virol 2012; 54: 282–5. CrossRef MEDLINE|
|29.||Burchard GD, Caumes E, Connor BA, et al.: Expert opinion on vaccination of travelers against Japanese encephalitis. J Travel Med 2009; 16: 204–16. CrossRef MEDLINE|
|30.||Solomon T: Flavivirus Encephalitis. N Engl J Med 2004; 351: 370–8. CrossRef MEDLINE|
|31.||Burchard, GD: Malaria ist die wichtigste Differenzialdiagnose. |
Fieber nach Tropenaufenthalt. Pharm Unserer Zeit 2010; 39: 28–33. CrossRef MEDLINE